Helix Acquisition Corp. II has issued proforma combined financial statements related to its recent merger and acquisition (M&A) transaction with BridgeBio Oncology Therapeutics, Inc. The transaction, which was finalized on August 11, 2025, involved Helix merging with BridgeBio Oncology, resulting in the formation of a combined entity now listed on the Nasdaq under the ticker symbol "BBOT." The financial statements highlight that prior to the closing of this de-SPAC transaction, Helix conducted a private placement financing, raising $260.9 million. The combined company received a total of $366.8 million, accounting for the PIPE financing and unredeemed cash, while also reflecting the transaction costs incurred by Helix. This strategic move aims to bolster the company's mission to develop transformative medicines targeting genetic diseases and cancers.